Clene Inc. is offering 1,219,513 common shares at $3.28 each, expecting approximately $4.0 million in proceeds before expenses. The funds are intended for general corporate purposes, including regulatory dialogue, filings and a new drug application for CNM-Au8, plus expanded access, potential commercialization and Manufacturing expansion.

Key Highlights

  • Certain Clene directors and officers have agreed to buy shares worth approximately $2.1 million.
  • Shares outstanding immediately after the offering are expected to total 14,213,981.
  • Clene Inc. is offering 1,219,513 shares of common stock.

Clene Inc. (NASDAQ: CLNN) is offering 1,219,513 shares of common stock at $3.28 per share, targeting approximately $4.0 million in proceeds before expenses. The funds are intended for general corporate purposes, including regulatory work and preparation of a new drug application for CNM-Au8.

Insider Participation and Share Count

Certain directors and officers have agreed to purchase approximately $2.1 million of the stock at the offering price. The shares carry a Par Value of $0.0001 per share. Clene expects 14,213,981 common shares to be outstanding immediately after the transaction, based on 12,994,468 shares outstanding as of September 14, 2026. Delivery of the shares is expected on or about September 16, 2026.